Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation

Journal of Alternative and Complementary Medicine

Volumn 20, Issue 6, 2014, Pages 479-485

  Kantor, Elizabeth D ^a,b,c   Lampe, Johanna W ^a,b   Navarro, Sandi L ^a   Song, Xiaoling ^a   Milne, Ginger L ^d   White, Emily ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHONDROITIN; GLUCOSAMINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; CYTOKINE;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DRUG USE; FEMALE; HOME; HUMAN; INFLAMMATION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OBESITY; PILL; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; PROTEIN BLOOD LEVEL; SUPPLEMENTATION; SYSTEMIC DISEASE; BLOOD; DIET SUPPLEMENTATION; METABOLISM; MIDDLE AGED;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHONDROITIN; CYTOKINES; DIETARY SUPPLEMENTS; FEMALE; GLUCOSAMINE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED;

EID: 84902297861     PISSN: 10755535     EISSN: 15577708     Source Type: Journal    
DOI: 10.1089/acm.2013.0323     Document Type: Article

References (37)

1. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008;300: 2867-2878.
2. Largo R, Alvarez-Soria MA, Díez-Ortego I, et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003;11: 290-298.
3. Xu CX, Jin H, Chung YS, et al. Chondroitin sulfate extracted from ascidian tunic inhibits phorbol ester-induced expression of Inflammatory factors VCAM-1 and COX-2 by blocking NF-kappaB activation in mouse skin. J Agric Food Chem 2008;56: 9667-9675.
4. Iovu M, Dumais G, du Souich P. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 2008; 16 Suppl 3:S14-18.
5. Sakai S, Sugawara T, Kishi T, et al. Effect of glucosamine and related compounds on the degranulation of mast cells and ear swelling induced by dinitrofluorobenzene in mice. Life Sci 2010;86: 337-343.
6. Chou MM, Vergnolle N, McDougall JJ, et al. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease- 9, and cartilage damage in arthritis. Exp Biol Med (Maywood) 2005;230: 255-262.
7. Largo R, Martinez-Calatrava MJ, Sanchez-Pernaute O, et al. Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. Am J Physiol Heart Circ Physiol 2009;297:H268-276.
8. Azuma K, Osaki T, Wakuda T, et al. Suppressive effects of N-acetyl-D-glucosamine on rheumatoid arthritis mouse models. Inflammation 2012;35: 1462-1465.
9. Campo GM, Avenoso A, Campo S, et al. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther 2003; 5:R122-131.
10. Campo GM, Avenoso A, Campo S, et al. Chondroitin-4- sulphate reduced oxidative injury in caerulein-induced pancreatitis in mice: the involvement of NF-kappaB translocation and apoptosis activation. Exp Biol Med (Maywood) 2008;233: 741-752.
11. Hua J, Sakamoto K, Kikukawa T, et al. Evaluation of the suppressive actions of glucosamine on the interleukin- 1beta-mediated activation of synoviocytes. Inflamm Res 2007;56: 432-438.
12. Arafa NM, Hamuda HM,Melek ST, et al. The effectiveness of Echinacea extract or composite glucosamine, chondroitin and methyl sulfonyl methane supplements on acute and chronic rheumatoid arthritis rat model. Toxicol Ind Health 2013;29: 187-201.
13. Wu YL, Kou YR, Ou HL, et al. Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol 2010;635: 219-226.
14. Yomogida S, Hua J, Sakamoto K, et al. Glucosamine suppresses interleukin-8 production and ICAM-1 expression by TNF-alpha-stimulated human colonic epithelial HT-29 cells. Int J Mol Med 2008;22: 205-211.
15. Nakamura H, Shibakawa A, Tanaka M, et al. Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol 2004;22: 293-299.
16. Chan PS, Caron JP, Orth MW. Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate. J Rheumatol 2006;33: 1329-1340.
17. Gouze JN, Bordji K, Gulberti S, et al. Interleukin-1beta downregulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta- mediated effects in rat chondrocytes. Arthritis Rheum 2001;44: 351-360.
18. Rajapakse N, Kim MM, Mendis E, et al. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via downregulation of mitogen-activated protein kinase-mediated nuclear factor-kappaB signaling. Immunology 2008;123: 348-357. (Pubitemid 351171187)
19. Nakamura H, Nishioka K. Effects of Glucosamine/ chondroitin supplement on osteoarthritis: involvement of PGE2 and YKL-40. J Rheum Joint Surg 2002;21: 175-184.
20. Kantor ED, Lampe JW, Vaughan TL, et al. Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol 2012;176:1002- 1013.
21. Cai Q, Gao YT, Chow WH, et al. Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J Clin Oncol 2006;24: 5010-5016.
22. Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a metaanalysis. Cancer Causes Control 2009;20: 15-26.
23. Emerging Risk Factors C, Kaptoge S, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant metaanalysis. Lancet 2010;375: 132-140.
24. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006;56: 69-83.
25. Touvier M, Fezeu L, Ahluwalia N, et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol 2013;177: 3-13.
26. Tsilidis KK, Branchini C, Guallar E, et al. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 2008;123: 1133-1140.
27. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm 2010; 2010:535918.
28. Satia JA, Littman A, Slatore CG, et al. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. Cancer Epidemiol Biomarkers Prev 2009;18: 1419-1428.
29. Brasky TM, Lampe JW, Slatore CG, et al. Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control 2011;22: 1333-1342.
30. Pocobelli G, Kristal AR, Patterson RE, et al. Total mortality risk in relation to use of less-common dietary supplements. Am J Clin Nutr 2010;91: 1791-1800.
31. Bell GA, Kantor ED, Lampe JW, et al. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol 2012;27: 593-603.
32. White E, Patterson RE, Kristal AR, et al. VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol 2004;159: 83-93.
33. Murphey LJ, Williams MK, Sanchez SC, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004;334: 266-275.
34. Nakamura H, Masuko K, Yudoh K, et al. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int 2007;27: 213-218.
35. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18: 6853-6866.
36. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004;279: 48487-48490.
37. de Jager W, Bourcier K, Rijkers GT, et al. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol 2009;10:52.